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Introduction
Primary Cutaneous  Anaplastic large‑Cell Lymphoma (PC‑ALCL) 
is the second most common cutaneous T‑cell Lymphoma [1]. (PC‑
ALCL) is part of  the spectrum of  CD30+ lymphoproliferative 
diseases of  the skin including lymphomatoid papulosis. PCALCL 
is composed of  large cells with an anaplastic, pleomorphic, or 
immunoblastic cytomorphology, and expression of  the CD30 
antigen by the majority (>75%) of  tumorcells [2]. PC‑ALCL 
remains confined to the skin with rare dissemination beyond local 
lymphnodes inmost cases [2]. PC‑ALCL must be distinguished 
from secondary cutaneous lesions of  systemic ALCL since the 
latter runs a poor clinical course [3]. PC‑ALCL mainly affects 
older patients in the sixth decade. We here by report a case of  
unusually aggressive PC‑ALCL in a young adult.
Case Report
A 34‑year‑old man with history of  chronic smoking, admitted to 
our departement for pigmented patchs on the trunk and scalp 
lasting for 3 years (Figure 1). The patient reported spontaneous 
regression in some lesions (Figure 2). The large lesion is localized 
in the chest (Figure) began as a small reddened patch and after 
3 month  became a 30‑cm, then 50cm raised, dark, ulcerative 
circular mass lesion (Figure 3). Lymphadenopathy was appreciated 
on physical examination. Histological and immunohistochemical 
study confirms primary cutaneous lymphoproliferation T CD30 
(+) consistent with an anaplastic lymphoma cutaneous CD30 
(+) Expressed by 75% of  atypical cells (Figure 4, 5). ALK was 
negative. Tumor extension assessment had not objectified extra 
cutaneous reached. The histological study of  surgical resection 
of  axillary lymphadenopathy was inflammatory. The patient has 
received treatment by methotrexate, then CHOEP chemotherapy, 
without improvement. The patient died of  septic shock.
Discussion
PCALCL CD30‑positive is the second most common form of  
cutaneous T‑cell Lymphoma (CTCL) with an incidence of  0.1 to 
0.2 patients per 100,000 [1]. It is mainly affects people in their 
sixth decade with a male to female ratio of  2 to 3/1 [1].
The criteria for the diagnosis of  PCALCL include: more than 
75% infiltration of  CD30+ large anaplastic cells in skinbiopsy, no 
clinical history of  lymphomatoid papulosis, mycosis fungoides or 
other cutaneous lymphomas, and no extra cutaneous localization 
after extensive investigations at presentation [4]. Our patient 
fulfilled all the criteria.
Clinically, it is solitary asymptomatic reddish to violaceous nodule, 
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plaque or tumor over the head, trunk and extremities. The lesion 
is often slow growing with an indolent clinical course and may 
present for a long time before being diagnosed [5], and may regress 
spontaneously in 30% of  cases [6]. However clinical presentation 
can be impressive with the rapid appearance of  a single purplish 
red tumor with necrotic evolution. In our case, evolution were 
insidious for 3 years with the notion of  spontaneous regression 
of  lesions, then becoming rapidly progressive with installation of  
more extensive ulcerated and necrotic tumors.
Generalized or multifocal lesions are rare and seen in about 20% 
of  the patients [2], they are not controlled by treatment with a 
risk of  secondary progression extracutaneous high relative to the 
localized form (17% versus 8%), and a higher mortality rate (12% 
versus 3%) [7].
PC‑ALCL is characterized histologically by dense cohesive sheets 
of  large atypical cells, known as “hallmark cells”, comprising 
Figure 1. Tumors on the Trunk and Scalp.
Figure 2. Spontaneous Regression in some Lesions on the Trunk.
Figure 3. Ulcerative Circular Mass Lesion.
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Figure 4. Epidermal ulceration, with Dense Lympoides infiltrates on the Dermis.
Figure 5. Immunohisto Chemical Study Confirms Primary Cutaneous Lympho Proliferation T CD30.
more than 75% of  the cellular infiltrate. The cells have abundant 
cytoplasm with reniform‑shaped hyperchromatic nuclei and 
prominent eosinophilic nucleoli with frequent mitoses [8], similar 
histological findings were observed in our case.
Nuclear matrix protein (NMP)‑ALK is a nuclear fusion protein, 
whichis not expressed in normal lymphocytes. ALK expression is 
common in systemic ALCL and rare in PC‑ALCL, its expression
in skin is a warning to look for systemic disease [3] specially nodal 
involvement. 
In our case, the ALK was negative, and the histological 
study of  surgical resection of  axillary lymphadenopathy was 
inflammatory confirming the primary cutaneous character of  
lymphoproliferation. Our patient is classified as stage T3bN0M0 
based on the TNM classification system for primary cutaneous 
lymphomas other than MF/SS of  the ISCL/EORTC [9].
Extracutaneous dissemination occurs in approximately 10% of  
patients with localized disease and mainly involves the regional 
lymphnodes, thus long‑term follow‑up is required in all patients 
with PCALCL.
The mechanisms that are involved in the development of  anaplastic 
large cell lymphoma are unknown [10]. In most patients, the initial 
step that involves activation and clonal expansion of  CD30+ T 
cells is controlled effectively by the host immune response [10]. 
Further progression occurs only when the tumor cells acquire a 
growth advantage, either by additional chromosomal alterations 
or when the host immune response becomes deficient [10].
However, there maybe spontaneous regression of  the lesion if  
the host immune responseis intact [10].
PC‑ALCL can lend confusion with transformed mycosis 
fungoides or with a lymphomatoid papulosis, hence the interest 
of  a clinicopathological confrontation.
Treatment of  PC‑ALCL should be decided according to the size, 
number and extent of  the tumor.
Primary C‑ALCL is an indolent disease, therefore treatment 
measures should focus on noninvasive strategies. Localized 
radiation therapy or surgical excision for solitary or localized 
lesionsis the preferred treatment for C‑ALCL [11]. Systemic 
therapy is indicated for patients refractory to local therapy, 
multifocal disease like our patient, and/or extracutaneous 
spread of  disease. A well‑tolerated option include slow‑dose 
methotrexate [12, 13], but unfortunately it was not effective 
in our case. Alternative therapies such as oral bexarotene, 
Interferon‑alpha (IFN), thalidomide, or doxorubicin may be used 
for treating PC‑ALCL [1, 14, 15].
Combination chemotherapy is not indicated in the first intension, 
but In view of  an aggressive clinical course, and based on 
the available research [11‑13], our patient was treated with 
chemotherapy type CHOEP. Unfortunately, this tumor has a 
tendency to recur, even after long disease‑free intervals. According 
to the literature review, multi agent systemic chemotherapy does 
not prevent future relapses [7].
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Newer classes of  drugs such as brentuximab vedotin (SGN35)
[16, 17], histone deacetylase (HDAC) inhibitors are now available 
as treatment alternatives. Recently Romidepsin was approved 
for treatment of  cutaneous ALCL for patients that had received 
systemic chemotherapy at least once [18].
In our patient, the refractory and debilitating multifocal shape was 
enough to indicate multiagent systemic chemotherapy. Moreover, 
the vital prognosis can be put into play by the iatrogenic 
immunosuppression.
Conclusion
Although they are exceptional, multifocal, recurrent and refractory 
forms seem very debilitating, having a fatal prognosis, and pose a 
problem of   management.
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